We’re excited to share that AB-1005, which is being developed for moderate Parkinson’s disease, received US FDA Fast Track and UK MHRA Innovation Passport designations. There's a huge unmet need for #Parkinson's treatment, and these designations take us another step closer to accelerating access for patients. We at #AskBio, alongside Bayer | Pharmaceuticals, are dedicated to providing patients with innovative therapies and, most importantly, improving patient outcomes. #genetherapy For Medical Media – Read our press release here: https://lnkd.in/g7Mr854f
Asklepios BioPharmaceutical, Inc. (AskBio)
Biotechnology Research
Research Triangle Park, North Carolina 35,236 followers
Pioneering science to create transformative molecular medicines.
About us
Asklepios BioPharmaceutical, Inc. (AskBio), a wholly owned and independently operated subsidiary of Bayer AG, is a fully integrated gene therapy company dedicated to developing life-saving medicines and changing lives. The company maintains a portfolio of clinical programs across a range of neuromuscular, central nervous system, cardiovascular and metabolic disease indications with a clinical-stage pipeline that includes therapeutics for congestive heart failure, Huntington’s disease, limb-girdle muscular dystrophy, multiple system atrophy, Parkinson’s disease, and Pompe disease. AskBio’s gene therapy platform includes Pro10™, an industry-leading proprietary cell line manufacturing process, and an extensive capsid and promoter library. With global headquarters in Research Triangle Park, North Carolina, and European headquarters in Edinburgh, Scotland, the company has generated hundreds of proprietary capsids and promoters, several of which have entered pre-clinical and clinical testing. Learn more at askbio.com. Vision - Pioneering science to create transformative molecular medicines. Mission - Lead innovative science and drive clinical outcomes to transform people's lives. Values: • Be a Pioneer. We are not afraid of the impossible and to innovate to make gene therapies accessible to those in need. • Cultivate Collaboration. Strive to be the best teammate, actively listen, openly communicate, and embrace diverse points of view. • Embrace Responsibility. We are humbled by the enormity of our mission. We hold a relentless commitment to advance science and clinical outcomes for our patients, families, and caregivers. • Raise the Bar. Continuously drive improvements and efficiencies. Seek and provide constructive feedback. Have a bias for learning and action. • Act with Uncompromising Integrity. Be honest, transparent, and committed to doing what’s right in every situation. Make clear commitments and follow through.
- Website
-
http://www.askbio.com
External link for Asklepios BioPharmaceutical, Inc. (AskBio)
- Industry
- Biotechnology Research
- Company size
- 501-1,000 employees
- Headquarters
- Research Triangle Park, North Carolina
- Type
- Privately Held
- Founded
- 2001
- Specialties
- AAV, Adeno-Associated Virus, Gene Therapy, Rare Disease, AAV Manufacturing, Molecular Medicine, Nucleic Acid, Epigenome, and Doggybone DNA
Locations
Employees at Asklepios BioPharmaceutical, Inc. (AskBio)
-
Javier Garcia
General Partner and Founder of Columbus Venture Partners | Chairman of the Board of Viralgen | Secretary of Fundación Columbus | Tambor de Oro 2023
-
Gustavo Pesquin
-
Doug Schantz
Senior Vice President of Clinical Operations at Asklepios BioPharmaceutical, Inc. (AskBio)
-
Kira Mourão MBCS
Principal Machine Learning Scientist at Asklepios BioPharmaceutical, Inc. - (AskBio)
Updates
-
As our friends and colleagues in the US pause to celebrate Independence Day, we’re reminded that the summer holiday season in North America and Europe provides the perfect opportunity for many of our employees to take a well-deserved break. In line with that, we instituted our “Summer Days” program, which provides #AskBio teams around the world with three additional days off that can be used between June and August. Happy 4th to everyone in the US and all the best to everybody this summer. #WorkLifeBalance
-
We’re excited to share that our Chief Scientific Officer, Mansuo L Shannon, has been elected to the #AskBio Board of Directors. She brings an important perspective and expertise to the Board and will be a key voice as we continue to develop our preclinical pipeline and platform technologies. We look forward to all that Mansuo will do to ensure that AskBio continues to innovate and remain at the leading edge of science. Congratulations, Mansuo! #Leadership #GeneTherapy
-
At #AskBio we believe strength lies in our diversity and our Employee Resource Groups help bring this to life through ongoing educational events and campus activities. A big thank you to our LGBTQ+ Employee Resource Group for planning and hosting a series of inspiring events to celebrate Pride Month. Pride Month is a time to honor the courage, resilience, and achievements of the LGBTQ+ community. It is a celebration of diversity, love, and the ongoing fight for equality. Let’s carry forward the spirit of Pride Month and continue to raise the bar, pioneer new paths, and celebrate the vibrant tapestry of our community. Together, we are stronger, more creative, and capable of achieving extraordinary things.
-
“Our goal is to harness the power of gene therapy to improve patient lives globally,” Jude Samulski, co-founder and current board member of AskBio states while sharing his insights on the future of #genetherapy in a recently published article in Nature. This article shines a light on AskBio’s pioneering spirit and unwavering commitment to forging a new path where gene therapy can transform countless lives. At #AskBio, we are on the forefront of innovation, dedicated to advancing research and embracing cutting-edge science to revolutionize the field of gene therapy and make strides for a brighter future for all. Read the article (accessible with a subscription) and let us know what you think. https://lnkd.in/efQHZcmj
-
At #AskBio we believe strength lies in our diversity and our Employee Resource Groups (ERGs) help bring this to life through ongoing educational events and campus activities. On the eve of Juneteenth, we gathered for an informative and engaging trivia session that not only tested our knowledge but also deepened our understanding of this pivotal moment in American history. Through fun and friendly competition, we explored the origins of Juneteenth, key historical figures, and significant milestones in the journey toward freedom and equality for all. The following day, we took time off to reflect on the significance of Juneteenth. This pause allowed us to contemplate the meaning of freedom and the ongoing struggle for equality. It's a reminder of the progress we've made and the work that still lies ahead. As we carry these lessons forward, on Thursday, June 27th our African American ERG will launch our third Summer Immersion Program. The program introduces junior and senior high school students from across North Carolina to a laboratory environment and also introduces them to careers in the biopharmaceutical industry. Together, we can reimagine what is possible. #leadership #genetherapy
-
Today we announced the initiation of recruitment to REGENERATE-PD, a Phase 2 clinical study assessing the efficacy and safety of AB-1005, an investigational #genetherapy for the treatment of moderate-stage Parkinson’s disease. More than 10 million people worldwide suffer from Parkinson’s disease, with approximately 1 million living in the United States. #AskBio is dedicated to advancing research and embracing cutting-edge science to explore gene therapy solutions for this debilitating disease. For Medical Media – Read our press release here: https://lnkd.in/g478gFVH #ParkinsonsDisease
-
This #PrideMonth, #AskBio is excited to celebrate with our LGBTQ+ colleagues and the broader community. Led by our Employee Resource Group, next week we’re hosting a series of educational events and celebrations to honor diversity, foster inclusion, and celebrate the unique identities that make our workplace vibrant and strong. Diversity is strength. Be who you are with Pride. #Pride2024
-
We’re excited to share the latest article from our CEO, Gustavo Pesquin, on the future of #genetherapy. #AskBio is proud to be part of the gene therapy revolution as we celebrate our milestones in #HeartFailure and #ParkinsonsDisease trials. Read more and join us for the journey. https://lnkd.in/emq7djZF
Advancing Innovative Science
Gustavo Pesquin on LinkedIn
-
The #AskBio team recently returned from the #IAPRD2024 World Congress in Lisbon. While on site, we engaged with various experts from the movement disorder community. Our experience was capped off by a packed house for an oral presentation by our VP of Global Clinical Development, Amber Van Laar, who delivered 18-month PD safety, preliminary efficacy, and imaging data for our Phase 1b clinical trial for AB-1005, an investigational #genetherapy for treating patients with Parkinson’s disease. (For more information about the AB-1005 Phase 1b Trial, visit clinicaltrials.gov (NCT#04167540). #Parkinsonsdisease